Bryan Garnier - 4D Pharma (DDDD) 4D Pharma â€˜Buggingâ€™ the immune system with LBPs

Report

Bryan Garnier

Olga Smolentseva

4D Pharma â€˜Buggingâ€™ the immune system with LBPs

4D Pharma is leveraging its proprietary microbiome-based MicroRx platform to create Live Biotherapeutic products (LBPs) that could modulate the immune repose. Companyâ€™s LBPs contain single bacterial strains that were identified based on their therapeutic potential. Considering an ample role of bacteria in shaping our immune system, we believe that 4Dâ€™s LBPs could be implemented in a wide range of indication, including immuno-oncology, inflammatory conditions of airways and GI, and CNS disorders.

30/07/2020 24 EN

Underlying

4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.

See profile

GB00BJL5BR07 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

Coverage dropped

October 11, 2022 October 11, 2022 1 EN

UOB

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

The yoy growth of total RSV was faster in Aug 22 (5.4%) than in Jul 22 (2.7%) on the low base in Aug 21. Despite near-term consumption being largely decided by the pandemic situation, we expect better consumption in 2H22 than in 1H22. We suggest watching four key areas in the consumer space: a) further increase in concentration (eg Jonjee), b) low penetration (eg duty-free), c) easing cost pressure (eg beer), and d) strong pricing power (eg Moutai). Maintain OVERWEIGHT on China’s consumer sector.

September 19, 2022 September 19, 2022 1 EN

BusinessWire

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. The ongoing study is being conducted in...

March 23, 2022 March 23, 2022 1 EN

BICO: CMD takeaways, a new vision amid tough market

Yesterday, BICO held a Capital Markets Day (CMD) where the new top executive management team provided an in-depth view of the renewed BICO 2.0 strategy. Aware of the Life Science (LS) Tools and Bioconvergence post-pandemic tough market conditions, the company's new vision focuses on Lab Automation

13h 13h 1 EN

Maria Vara

Maria Vara

XVIVO: acquisition of an innovative communication platform to save more lives

XVIVO is expanding its service offering with the acquisition of the FlowHawk software platform from OmniLife, aiming to streamline the complex planning and communication involved in organ transplantation, ensuring that "no one should die waiting for a new organ." The FlowHawk platform has proven it

21h / 30m 21h / 30m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Carbios: partnership with Sleever

Yesterday, Carbios announced it had signed an agreement with Sleever, a French leader in shrinksleeve label technology, for an exclusive, long-term contract to jointly develop biodegradable shrink films. This signature confirms Carbios' leadership in enzyme engineering and interest from partners in

21h / 36m 21h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

4D Pharma â€˜Buggingâ€™ the immune system with LBPs

Coverage dropped

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

BICO: CMD takeaways, a new vision amid tough market

XVIVO: acquisition of an innovative communication platform to save more lives

Carbios: partnership with Sleever

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe